However, it is noteworthy that several large-scale genomic studies recently found that the ZEB1 gene, which is a potent transcriptional repressor of GATA-3, is somatically targeted by deleterious mutations or deleted in 45–65 % of patients with advanced CTCL [19, 21, 22, 25]. Here, ZEB1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.